Skip to Main Content

After a defeat in federal court, the Department of Health and Human Services withdrew an advisory opinion which said drug makers participating in a controversial federal program must offer discounts through pharmacies that contract with hospitals serving low-income patients.

However, HHS simultaneously maintained the move does not have any bearing on a separate set of “violation” letters sent last month to six drug makers, which could face fines for failing to offer discounts through the 340B drug discount program for safety-net hospitals and clinics. The agency said the letters should be viewed as distinct from the opinion and that enforcement action can be pursued.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment